HNF4A HNF4A P2 Block rs2144908

HNF4A P2 rs2144908 — Tuning the Beta-Cell Master Switch

HNF4A | Hepatocyte Nuclear Factor 4 Alpha — a nuclear receptor transcription factor
essential for pancreatic beta-cell identity, hepatic lipid metabolism, and glucose
homeostasis is one of the most important
metabolic transcription factors in the body. Unlike many diabetes genes that act through
a single pathway, HNF4A controls the expression of dozens of downstream targets including
GLUT2 (glucose transporter), glucokinase, mitochondrial enzymes, and other transcription
factors such as HNF1A. Loss-of-function mutations in HNF4A cause
MODY1 | Maturity-Onset Diabetes of the Young type 1 — a monogenic, autosomal dominant
diabetes caused by HNF4A haploinsufficiency in beta cells; characterised by early-onset
non-insulin-dependent diabetes in lean individuals.

rs2144908 sits in an intron of HNF4A on the GRCh38 plus strand (chr20:44,357,077)
and is one of four variants — along with rs4810424, rs1884613, and rs1884614 — that
define the common HNF4A P2 promoter haplotype block. This block tags regulatory
variation in the P2 promoter, the alternative upstream promoter that drives HNF4A
expression specifically in pancreatic beta cells (and, to a lesser extent, fetal liver).

The Mechanism

The HNF4A gene has two functional promoters. The P1 promoter is active in adult liver
and drives the HNF4A1–6 isoform family. The P2 promoter is active in pancreatic beta
cells and drives the HNF4A7–12 family — also known as the "fetal" isoforms — which
persist into adulthood in the pancreas. The P2 promoter is controlled partly by HNF1A,
creating a transcriptional feedback circuit: HNF4A (P2 isoform) → HNF1A → HNF4A,
which is disrupted by variants in either gene, as confirmed by
Kind et al. 2024 (Diabetes) | HNF-1A mediates HNF4A P2 promoter regulation; P2-linked
mutations impair glucose-stimulated insulin secretion in beta cells. Diabetes, 2024.

The A allele at rs2144908 tags a P2 haplotype associated with mildly reduced P2
promoter activity in beta cells — or altered responsiveness of the promoter to
transcriptional activators. The consequence is reduced HNF4A protein in beta cells,
which impairs the cell's ability to ramp up insulin secretion in response to rising
blood glucose. In the adult liver, the same P2 isoform becomes
aberrantly re-expressed in type 2 diabetes | Chronically elevated P2 isoform in
diabetic liver promotes excess hepatic glucose production through a
glucagon→TET3→FOXA2→P2 demethylation axis, compounding hyperglycemia on top of
impaired insulin secretion. The A allele
at rs2144908 thus implicates both pancreatic and hepatic arms of glucose dysregulation.

The Evidence

The HNF4A P2 haplotype was originally identified in Finnish and Ashkenazi populations
in 2004, and rs2144908 was one of the four SNPs used by
Weedon et al. 2004 | Common variants of the hepatocyte nuclear factor-4alpha P2
promoter are associated with type 2 diabetes in the U.K. population. Diabetes, 2004
to tag the risk haplotype in 5,256 UK subjects, where the risk haplotype carried an
OR of 1.15 (95% CI 1.02–1.33, P=0.02). A 2007 Norwegian population study and
meta-analysis by
Johansson et al. | Studies in 3,523 Norwegians and meta-analysis in 11,571 subjects
indicate HNF4A P2 region variants are associated with type 2 diabetes in Scandinavians.
Diabetes, 2007
reported rs2144908 itself with OR 1.21 (95% CI 1.05–1.38) in the Norwegian cohort,
and a Scandinavian-restricted meta-analysis OR of 1.14 (1.06–1.23, P=0.0004) for
the lead P2 tag SNP rs1884613.

In North Indian subjects, Chavali et al. 2011 | Association of variants in genes
involved in pancreatic beta-cell development and function with type 2 diabetes in
North Indians. J Hum Genet, 2011
found rs2144908 significantly associated with T2D (OR 1.37, 95% CI 1.20–1.57,
P=6.0×10⁻⁶) in 2,025 subjects, with the effect notably stronger in normal-weight
individuals — consistent with a primary beta-cell deficiency mechanism rather than
an obesity-driven insulin resistance pathway.

The A allele is the minor allele in Europeans (~17%) and Africans (~11%), but has
much higher frequency in East Asians (~46%) and South Asians (~27%). Effect sizes
have been inconsistent across populations, partly because the causal functional
variant within the P2 haplotype block has not been definitively identified, and the
LD pattern between rs2144908 and the true causal variant differs by ancestry.

Practical Actions

The A allele at rs2144908 modestly impairs glucose-stimulated insulin secretion
through reduced HNF4A activity in beta cells. For heterozygous AG carriers (the
most common at-risk genotype), the risk elevation per allele is modest (OR ~1.15–1.21),
equivalent to roughly a 15–20% increase in relative risk for type 2 diabetes. This
is not alarming in isolation, but becomes clinically meaningful when combined with
additional T2D risk factors (family history, excess weight, sedentary lifestyle,
other T2D-associated variants). Periodic monitoring of fasting glucose and HbA1c is
the core intervention, since early detection of prediabetes enables lifestyle changes
that can prevent progression. Reducing postprandial glucose spikes through low-glycemic-
index carbohydrate choices directly compensates for reduced beta-cell secretory reserve.

For homozygous AA carriers, who carry both copies of the risk haplotype, an oral
glucose tolerance test (OGTT) provides more sensitive detection of beta-cell secretory
impairment than fasting glucose alone, since the OGTT specifically challenges the
glucose-stimulated insulin secretion pathway disrupted by this locus.

Interactions

rs2144908 is in strong linkage disequilibrium (D' > 0.97, r² > 0.90) with rs4810424,
rs1884613, rs1884614, and rs6031552 — all of which tag the same P2 haplotype block.
These variants do not represent independent risk signals; they capture the same
underlying haplotype. Carrying risk alleles at multiple P2 block SNPs does not add
cumulative independent risk beyond the haplotype itself.

Functionally, HNF4A and KCNJ11 (rs5219, Kir6.2 E23K) interact: HNF4A is a known
transcriptional regulator of the KCNJ11 gene. Qi et al. 2007 | Gene-gene interactions
between HNF4A and KCNJ11 in predicting type 2 diabetes in women. Diabet Med, 2007
found significant interactions between HNF4A rs2144908 and KCNJ11 E23K in predicting
T2D risk in women (P=0.017), with combined minor allele carriage substantially elevating
risk above either variant alone. TCF7L2 rs7903146 (Wnt/incretin pathway) impairs a
third independent beta-cell secretory mechanism; carriers of both HNF4A P2 and TCF7L2
risk alleles face compounded beta-cell dysfunction warranting earlier glucose monitoring.